A new technology offers treatment for HIV infection through a single injection - World Pharma News

According to the article:

"Currently, the researchers explain, there is no genetic treatment for AIDS, so the research opportunities are vast. Dr. Barzel concludes: "We developed an innovative treatment that may defeat the virus with a onetime injection, with the potential of bringing about tremendous improvement in the patients' condition. When the engineered B cells encounter the virus, the virus stimulates and encourages them to divide, so we are utilizing the very cause of the disease to combat it. Furthermore, if the virus changes, the B cells will also change accordingly in order to combat it, so we have created the first medication ever that can evolve in the body and defeat viruses in the 'arms race'.

Based on this study we can expect that over the coming years we will be able to produce in this way a medication for AIDS, for additional infectious diseases and for certain types of cancer caused by a virus, such as cervical cancer, head and neck cancer and more."

Read the full source article: A new technology offers treatment for HIV infection through a single injection - World Pharma News

FDA Approves First Long-Acting HIV Drug Combo - VOA

• FDA cGMP QSR GMP Online Training - trusted cGMP online training classes offered by SkillsPlus International Inc. 

According to the article:

"The two-injection combination treatment is called Cabenuva. The drug is expected to make it easier for people to receive their HIV medicines and to do so with more privacy. The injections mark a big change from methods used in the past. Those treatments required patients to take multiple pills several times a day, carefully timed around meals.

Dr. Steven Deeks is an HIV specialist at the University of California, San Francisco. He told The Associated Press that the new treatment can make patients’ lives better because it is only needed once a month. “People don’t want those daily reminders that they’re HIV infected,” Deeks said."

Read the full source article:  FDA Approves First Long-Acting HIV Drug Combo - VOA

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment - FDA.gov

• FDA cGMP QSR GMP Training Courses - by SkillsPlus International Inc.

Read the full press release:

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment - FDA.gov

The U.S. Food and Drug Administration . . .

"approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV. 

“Currently, the standard of care for patients who have never been treated is a three-drug regimen. With this approval, patients who have never been treated have the option of taking a two-drug regimen in a single tablet while eliminating additional toxicity and potential drug interactions from a third drug,” said Debra Birnkrant, M.D., Director of the Division of Antiviral Products. “Having a drug-sparing treatment available that uses fewer drugs is beneficial to patients who may have issues taking multiple medications over a long period of time.”"

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

#FDA

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
Designated Rep Certification Class
CA Designated Representative Training Program
California Designated Representative Training Program
California HMDR Exemptee Training
Exemptee Certification Class
FL CDR Exam Prep
SkillsPlus Intl Inc. - The Leader in Compliance Training
The Health, Drug, Prescription, and GMP Supersite Gift Store 

CRISPR kills HIV and eats Zika 'like Pac-man'. Its next target? Cancer | WIRED UK

Read the full article:  CRISPR kills HIV and eats Zika 'like Pac-man'. Its next target? Cancer | WIRED UK:

"These new enzymes are variants of a CRISPR protein, Cas13a, which the UC Berkeley researchers reported last September in Nature, and could be used to detect specific sequences of RNA, such as from a virus. The team showed that once CRISPR-Cas13a binds to its target RNA, it begins to indiscriminately cut up all RNA making it "glow" to allow signal detection."

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
The Health, Drug, Prescription, and GMP Supersite Gift Store 

Injections given every 8 weeks suppress HIV just as well as daily pills, trial finds - ScienceAlert

Updated December 21, 2021

You might also be interested in:

FDA approves first injectable HIV prevention drug - Rather than as a daily pill, the newly approved drug, Apretude, is given to patients every two months - NBC News

---  the original post follow below  ---

Read the full article: Injections given every 8 weeks suppress HIV just as well as daily pills, trial finds - ScienceAlert:

"Formulated to be long-acting and injected together, these two drugs suppressed the virus at a comparable rate to a combination of similar-acting pills taken daily. Patients received one shot either every four weeks, or every eight weeks, and the virus suppression rates were basically the same, although patients with monthly injections complained more about pain at the injection site – the most common side effect of this treatment."

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

Scientists Find a Way to Block HIV from Infecting Healthy Cells | TIME

Read the full article: Scientists Find a Way to Block HIV from Infecting Healthy Cells | TIME:

"Michael Farzan, professor of infectious diseases at Scripps Research Institute, and his team used a gene therapy technique to introduce a specific HIV disruptor that acted like gum on HIV’s keys. Once stuck on the virus’s surface, the peptide complex prevents HIV from slipping into the molecular locks on healthy cells. "

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

World AIDS Day - FDA Voice

• Respected FDA CGMP online training courses and programs taught by SkillsPlus International Inc.

Updated February 15, 2022

The original link broke.

You can still read about the same topic here:

World AIDS Day - CDC.gov

---  the original post follows below  ---

World AIDS Day | FDA Voice:

"The Food and Drug Administration supports the fight against HIV/AIDS by promoting medical innovation, protecting the blood supply, and reviewing and regulating new and existing medical products, including devices used in prevention, such as condoms and medical gloves. Doctors, nurses, pharmacists, scientists and many others at FDA have worked hard in 2012 to make sure that there are safe and effective medical products and devices available to fight HIV/AIDS."

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

FDA approves first drug for reducing the risk of sexually acquired HIV infection

Updated June 19, 2025

The original post has gotten very out of date.

You might be interested in this more current announcement, Breakthrough: FDA Approves Injection to Prevent HIV:

https://www.sciencealert.com/breakthrough-fda-approves-injection-to-prevent-hiv

---  the original post follows below  ---

This is considered pivotal in the 30-year battle against AIDS.

Press Announcements > FDA approves first drug for reducing the risk of sexually acquired HIV infection:

"Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.

The FDA previously approved Truvada to be used in combination with other antiretroviral agents for the treatment of HIV-infected adults and children 12 years or older.

As part of PrEP, HIV-uninfected individuals who are at high risk will take Truvada daily to lower their chances of becoming infected with HIV should they be exposed to the virus. A PrEP indication means Truvada is approved for use as part of a comprehensive HIV prevention strategy that includes other prevention methods, such as safe sex practices, risk reduction counseling, and regular HIV testing."

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, popular QSR training, respected instructors
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

Clinical Study Of Disulfiram To Reduce HIV Reservoir

Image via WikipediaThis caught my eye while scanning health news, Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals.

This ClinicalTrials.gov notice provides robust details about the research study, which is actively recruiting participants.

I find the basis for the study pretty interesting:

"Our primary hypothesis is that disulfiram will reduce the latent reservoir of HIV-1 in patients on highly active antiretroviral therapy (HAART). Theoretically, disulfiram will force HIV to replicate (grow) and thus result in the death of the infected cell. Standard antiretroviral drugs should prevent new cells from becoming infected. The end result of this process is that the total amount of HIV in the body will decline over time."

Return Home: http://drughealth.blogspot.com/

Preventive Anti-HIV Drug Use - Cautious Prescribing

The CDC just published, Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men.

In a nutshell:

The report provides interim guidance to health-care providers based on the reported results of the trial, which indicated that tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.

You might also be interested in:
The CDC on Pre-Exposure Prophylaxis (PrEP)

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store

Daily Truvada Lowers AIDS Risk

Image via Wikipedia

• Trusted FDA cGMP online training courses and programs taught by SkillsPlus International Inc.

Updated March 15, 2022

You might also be interested in:

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention - Drug Given Every Two Months Rather Than Daily Pill is Important Tool in Effort to End the HIV Epidemic - FDA.gov

---  the original post follows below  ---

The New York Times reports, Daily Pill Greatly Lowers AIDS Risk, Study Finds.

Promising results found that the men taking Truvada, a common combination of two antiretroviral drugs, were 44 percent less likely to get infected with the virus that causes AIDS than an equal number taking a placebo.

Return Home: http://drughealth.blogspot.com/

World AIDS Day - Bewildering Number of Official Websites

Today is World AIDS Day. If you Google it, you'll end up finding a dizzying array of websites proclaiming to be the official website for the Day.

Here's my contribution to the conversation. I recommend this helpful US Government site, AIDS.gov.  The opening line on the site just about sums up what they offer, "An estimated 1.1 million Americans are living with HIV, and yet one out of five don’t know it. World AIDS Day (December 1) is an opportunity for us to take action! Here are a few simple, powerful, and engaging ways:..."

Return Home: http://drughealth.blogspot.com/

New Gel Reduces HIV Infection in Women

Updated July 1, 2025

The report of the results of Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial. 

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors

Promising New HIV Antibody Discovered

This is an exciting new finding.

For more details, read this Medical News Today article, Antibodies That Prevent Most HIV Strains From Infecting Human Cells Will Advance HIV Vaccine Design, Antibody Therapy For Other Diseases.

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store

FDA Webinar on Access to Investigational Drugs

• People also search for FDA CGMP Online Training - trusted GMP online training courses provided by SkillsPlus International Inc.

Updated April 17, 2021

The original link broke.

You might also be interested in:

Training and Continuing Education - Educational resources and training opportunities for healthcare professionals, industry, consumers, and academia - FDA.gov

---  the original post follows below  ---

The FDA is hosting a webinar where you can learn more about access to investigational drugs. The featured speakers, Theresa Toigo, Director, Office of Special Health Issues and Richard Klein, HIV/AIDS Program Director, Office of Special Health Issues, will discuss what to consider when deciding whether to seek access to an investigational drug and the ways to access investigational drugs. There will be time for questions following the presentation. The 30 minute webinar will be held Tuesday, February 23, at 3 p.m. ET.

You can find out more information about the webinar, including how to participate in the webinar, on the Upcoming Webinar on Access to Investigational Drugs web page.

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store

 

HIV AIDS - 97 US Medicines in Testing - PharmaTimes

Image via Wikipedia

Updated November 26, 2025

The original link broke.

You can still read about the same topic here:

U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS - MedIndia:
https://www.medindia.net/health-press-release/US-Pharmaceutical-Companies-Developing-97-New-Drugs-and-Vaccines-to-Fight-HIVAIDS-53732-1.htm

---  the original post follows below  ---

This is a really nice snapshot of some of the clinical testing going on in the HIV AIDS field, PhRMA's Pharmaceutical Researchers Are Testing 97 Medicines And Vaccines for HIV and Related Conditions. The article provides a quick overview for medicines grouped by:

1. Anticancer
2. Antiviral
3. Gene therapy
4. Immunomodulators
5. Vaccines
6. Other

Previous Posts: Abzymes Pinpoint The HIV Achilles Heel 109 HIV Drugs And Vaccines Under Development Listen To People With AIDS and HIV (audio)

Return Home: http://drughealth.blogspot.com/ 

Recent HIV Vaccine Study Results - Could be disappointing

Image via Wikipedia

Updated January 14, 2024

You might also be interested in:

HIV vaccine research ‘at a crossroads’ after recent failures - Healio

---  the original post follows below  ---

Optimism generated from a recent HIV vaccine study conducted by the US Army & Thailand, might not be justified after all, reports this Wall Street Journal article, Data Call Into Question HIV Study Results. The statistical analysis is discussed, and calls into question the conclusions reached and recently publicized. I think there's more to come on this. 

Return Home: http://drughealth.blogspot.com/ 

New HIV Antibodies Hold Promise For Vaccines

Image via Wikipedia

Scientists at the Scripps Research Institute report promising findings in their research report, Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. According to this LA Times news article, Antibodies found that prevent HIV from causing severe AIDS, this means that they have isolated two so-called broadly neutralizing antibodies (bNAbs) that can block the action of many strains of HIV, the virus responsible for AIDS. Other bNAbs against HIV have been discovered before, but PG9 and PG16 are the first to be isolated in over 10 years from donors in developing countries, where most new HIV infections occur. Also, the previously identified bNAbs bind to spots on the virus that are hard to target with vaccines. These new antibodies, which are more potent than other antibodies described to date while maintaining great breadth, attach to a novel, and potentially more accessible site on HIV to facilitate vaccine design. 

Return Home: http://drughealth.blogspot.com/ 

HIV AIDS Update - Obama strategy and more (podcast)

Image via Wikipedia

Listen to Ernest Hopkins, the San Francisco AIDS Foundation's Director of Federal Affairs, as he talks about the Obama administration's progress on the National AIDS Strategy, the recent White House reception with LGBT leaders on the 40th anniversary of the Stonewall riots and the progress being made toward lifting the US ban on HIV-positive foreign travelers, in this podcast, SFAF.org Podcast #58 - A Federal HIV/AIDS Update with Ernest Hopkins. 

Return Home: http://drughealth.blogspot.com/ 

Start HIV Meds Early - Live Longer

Updated May 7, 2021

Original links broke.

You can still read about the topic here:

Early initiation of antiretroviral therapy improves HIV survival rates, study says - Medical Life Sciences News

---  the original post follows below  ---

This Medical News Today article reports, "Early Initiation Of Antiretroviral Therapy Improves HIV Survival Rates, Study Says." The study results are available on the New England Journal of Medicine (NEJM) site, "Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. This recent research "provides evidence that patients would live longer if antiretroviral treatment was begun when their CD4+ count was above 500." As with these kinds of studies, there's also the counterpoint opinion, such as this editorial, "When To Start Antiretroviral Therapy: Ready When You Are?" .... darn, NEJM truncated it... go back to the Medical News Today article, they summarize the gist of the editorial. 

Related Posts: New Guidelines Released for HIV Opportunistic Infections HHS Updates HIV Treatment Guidelines (free pdf) Flash - HIV Drug Treatment Needs To Start Earlier 

Return Home: http://drughealth.blogspot.com/